

**Supplementary Table S1.** Baseline characteristics for sensitiviy analysis

Variables	Pre-Match			Post-Match		
	Control N= 283	PCS N= 239	STD	Control N= 167	PCS N= 167	STD
Sex (male)	173 (61.1)	136 (56.9)	0.06	102 (61.1)	94 (56.3)	0.1
Age (years)	53.8 ± 14.4	54.0 ± 14.0	0.01	53.6 ± 14.5	54.6 ± 13.7	0.07
Diagnosis						
Kidney transplantation	193 (68.2)	205 (85.8)	0.4	141 (84.4)	141 (84.4)	0
Chronic kidney disease	74 (26.2)	60 (25.1)	-0.02	44 (26.4)	45 (27.0)	-0.01
Kidney donor	40 (14.1)	10 (4.2)	-0.4	7 (4.2)	8 (4.8)	-0.02
Hypertension	159 (56.2)	184 (77.0)	0.5	109 (65.3)	121 (72.5)	0.1
Diabetes Mellitus	75 (26.5)	104 (43.5)	0.4	55 (32.9)	67 (40.1)	0.1
Dyslipidemia	176 (68.2)	175 (73.2)	0.2	121 (72.5)	122 (73.1)	0.01
Number of oupatient visits	6.9 ± 3.5	10.4 ± 5.3	0.8			0.07
Number of medications	7.4 ± 7.1	13.3 ± 10.4	0.7			0.1
Medications						
Diuretics	31 (11.0)	71 (29.7)	0.5	24 (14.4)	31 (18.6)	0.1
Potassium-lowering agents	5 (1.8)	14 (5.9)	0.2	5 (3.0)	4 (2.4)	-0.03
Alkalizing agents	11 (3.9)	31 (13.0)	0.3	8 (4.8)	8 (4.8)	0
Antibiotics	82 (29.0)	116 (48.5)	0.4	61 (36.5)	68 (40.7)	0.09
Immunosuppressants	196 (69.3)	205 (85.8)	0.4	141 (84.4)	141 (84.4)	0
CKD_MBD medications	34 (12.0)	59 (24.7)	0.3	25 (15.0)	24 (14.4)	-0.02
Laboratory findings						
Serum creatinine (mg/dL)	1.29 ± 0.7	1.5 ± 1.0	0.3	1.29 ± 0.7	1.3 ± 0.7	0.04
BUN (mg/dL)	19.39 ± 9.5	24.1± 13.1	0.4	20.6 ± 11.3	21.2 ± 9.2	0.06
eGFR(mL/min/1.73m <sup>2</sup> )	64.49 ± 21.4	55.9 ± 23.2	-0.4	62.5 ± 21.6	60.3 ± 21.6	-0.1
Calcium (mg/dL)	9.4 ± 0.4	9.3 ± 0.5	-0.2	9.4 ± 0.5	9.3 ± 0.5	-0.06
Cholesterol (mg/dL)	182.1 ± 30.1	181.7 ± 33.5	-0.01	184.0 ± 29.7	182.4 ± 32.8	-0.05
Glucose (mg/dL)	108.1 ± 25.5	113.7 ± 44.0	0.2	111.9 ± 30.1	114.1 ± 43.4	0.06
Hemoglobin (g/dL)	13.6 ± 1.7	13.2± 0.8	-0.2	13.5 ± 1.8	13.3 ± 1.8	-0.1
Albumin (g/dL)	4.5 ± 0.3	4.3 ± 0.4	-0.3	4.4 ± 0.4	4.4 ± 0.4	-0.08
Total bilirubin (mg/dL)	0.8 ± 0.3	0.8 ± 0.3	0.2	0.8 ± 0.4	0.8 ± 0.3	-0.04
Uric acid (mg/dL)	5.8 ± 1.5	6.1 ± 1.7	0.2	5.8 ± 1.5	5.9 ± 1.6	-0.1
Platelet (10 <sup>9</sup> /L)	224.2 ± 57.5	221 ± 59.0	-0.06	222.7 ± 60.5	223.2 ± 59.9	0.01
White Blood Cell (10 <sup>9</sup> /L)	7.0 ± 1.9	7.4 ± 2.5	0.2	7.2 ± 1.9	7.3 ± 2.3	0.07

**Supplementary Table S2.** Sensitiviy Analysis for Study Outcomes

Outcomes	Incidence or measured change		aOR or P value
	Control	PCS	
<i>End Stage Renal Disease</i>	30/167 (17.9)	19/167(11.3)	0.34 (0.14 – 0.78)
<i>Change in estimated glomerular filtration rate between before and after study period.</i>	-6.8 mL/min/1.73m <sup>2</sup>	-1.7 mL/min/1.73m <sup>2</sup>	0.06

Values are represented as number (%); aOR, adjusted odds ratio; PCS, pharmaceutical care services;